Overview

Using MASL to Combat Oral Cancer

Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This project will evaluate the expression of a receptor called podoplanin (PDPN) in cells from oral cancers and precancerous lesions. We will also determine how sensitive oral cancer cells are to a potential drug called Maackia amurensis seed lectin (MASL).
Phase:
Early Phase 1
Details
Lead Sponsor:
Rowan University
Collaborator:
Rutgers University
Treatments:
Lectins